Thyrotropin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Thyrotropin
Accession Number
DB15263
Type
Biotech
Groups
Investigational
Description

Thyrotropin is under investigation in clinical trial NCT01348191 (Detection of Thyrotrophin Receptor in Human Myometrium).

Synonyms
  • THYROTROPHIN
Categories
UNII
02KSI6Z9AK
CAS number
9002-71-5

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Thyrotropin.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Thyrotropin.
3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinoneThe therapeutic efficacy of Thyrotropin can be decreased when used in combination with 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Thyrotropin.
AcalabrutinibThe therapeutic efficacy of Thyrotropin can be decreased when used in combination with Acalabrutinib.
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Thyrotropin.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Thyrotropin.
AfatinibThe therapeutic efficacy of Thyrotropin can be decreased when used in combination with Afatinib.
AlaproclateThe therapeutic efficacy of Thyrotropin can be decreased when used in combination with Alaproclate.
AldesleukinThe therapeutic efficacy of Thyrotropin can be decreased when used in combination with Aldesleukin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Thyroid-stimulating_hormone
ATC Codes
V04CJ01 — Thyrotropin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentBenign Nontoxic and Toxic Goiter / Graves' Disease1
2CompletedTreatmentGoiter, Nodular1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 09:05 / Updated on February 02, 2020 03:21